|
|
||||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
The American Cancer Society estimates that colorectal
cancer will be diagnosed in 147,000 Americans in 2003 and will cause 57,100
deaths, making it the second-leading cancer killer. A seven-year randomized, double-blind study lead by Overall, study participants treated with a daily dose of
baby aspirin found their risk of polyps reduced 19% and their risk of
advanced lesions reduced by more than 40%. Another study, conducted among
patients with a history of cancer of the colon or rectum, tested with a
regular 325mg aspirin tablet against placebo, showed a 35% reduction in the
occurrence of adenoma. This research provides support for the emerging theory
that non-steroidal anti-inflammatory
drugs (NSAIDs), such as aspirin, may reduce a variety of
malignancies. Although there is
evidence that inflammation plays a role in many cancers, the strongest
support for the beneficial effects of NSAIDs has been for colorectal cancer.
Previous non-randomized studies have found that people who were taking
aspirin for a variety of reasons, such as to reduce the risk of heart disease
or alleviate arthritis pain, were less likely to develop colon cancer. This technology is claimed in
the published United States Patent Application Nos. 10/382,172 and 10/506,109. We are seeking an industrial partner
interested in its commercialization. (Ref: J188) |
||
|
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
||
|
|
||||
|
11 Rope Ferry Road #6210 |
||||
|
Hanover, NH 03755-1404 |
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|
